The price of Nektar Therapeutics (NASDAQ:NKTR) shares last traded on Wall Street rose 26.92% to $1.32.
NKTR stock price is now 74.45% away from the 50-day moving average and 113.97% away from the 200-day moving average. The market capitalization of the company currently stands at $242.38M.
, while ‘Jefferies’ rates the stock as ‘Hold’
In other news, ROBIN HOWARD W, President & CEO sold 20,033 shares of the company’s stock on Feb 20 ’24. The stock was sold for $13,622 at an average price of $0.68. Upon completion of the transaction, the President & CEO now directly owns 879,889 shares in the company, valued at $1.16 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 20 ’24, Chief R&D Officer Zalevsky Jonathan sold 9,014 shares of the business’s stock. A total of $6,130 was realized by selling the stock at an average price of $0.68. This leaves the insider owning 265,025 shares of the company worth $0.35 million. A total of 2.98% of the company’s stock is owned by insiders.
During the past 12 months, Nektar Therapeutics has had a low of $0.41 and a high of $1.13. As of last week, the company has a debt-to-equity ratio of 1.76, a current ratio of 6.45, and a quick ratio of 6.14. The fifty day moving average price for NKTR is $0.7568 and a two-hundred day moving average price translates $0.6172 for the stock.
The latest earnings results from Nektar Therapeutics (NASDAQ: NKTR) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at -$0.22, missing analysts’ expectations of -$0.21 by -0.01. This compares to -$0.31 EPS in the same period last year. The net profit margin was -306.31% and return on equity was -110.95% for NKTR. The company reported revenue of $23.89 million for the quarter, compared to $22.02 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 8.45 percent. For the current quarter, analysts expect NKTR to generate $15.34M in revenue.
